scholarly journals The Relationship between Antisocial and Borderline Features and Aggression in Young Adult Men in Treatment for Substance Use Disorders

2016 ◽  
Vol 48 (2) ◽  
pp. 115-123 ◽  
Author(s):  
Ryan C. Shorey ◽  
JoAnna Elmquist ◽  
Scott Anderson ◽  
Gregory L. Stuart
2010 ◽  
Vol 15 (8) ◽  
pp. 1829-1833 ◽  
Author(s):  
Christina S. Meade ◽  
Garrett M. Fitzmaurice ◽  
Amy K. Sanchez ◽  
Margaret L. Griffin ◽  
Leah J. McDonald ◽  
...  

Author(s):  
S. Janet Kuramoto-Crawford ◽  
Holly C. Wilcox

Intentional injuries affect millions of lives worldwide. The authors provide an overview of the epidemiological and preventive evidence on the relationship between substance use disorders (SUD) and intentional injuries. Emphasis is placed on suicide and intimate partner violence, as each area has received substantial research attention in relation to SUD. There is robust epidemiological evidence on the relationship between SUD, notably with alcohol use disorders, and most intentional injuries. Research has focused on the identification of factors that distinguish individuals with alcohol use disorders who are at particularly high risk for intentional injuries. Characterization of those with other drug use disorders who are at risk for engaging in intentional injuries and the role of SUD in intentional injuries has been less extensively investigated. The authors conclude with a discussion of public health approaches to the prevention of intentional injuries among individuals with SUD.


2002 ◽  
Vol 43 (4) ◽  
pp. 245-252 ◽  
Author(s):  
Renee D. Goodwin ◽  
David A. Stayner ◽  
Matthew J. Chinman ◽  
Ping Wu ◽  
Jacob Kraemer Tebes ◽  
...  

2014 ◽  
Vol 140 ◽  
pp. e112-e113
Author(s):  
Magdalena Kulesza ◽  
S.E. Ramsey ◽  
R. Brown ◽  
M.E. Larimer

2019 ◽  
Vol 8 (7) ◽  
pp. 1058 ◽  
Author(s):  
Albert Batalla ◽  
Hella Janssen ◽  
Shiral S. Gangadin ◽  
Matthijs G. Bossong

The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the efficacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined possible profiles of patients who may benefit the most from CBD treatment. CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness. A potential biomarker is the level of anandamide in blood. CBD and THC mixtures showed positive effects in reducing short-term withdrawal and craving in cannabis use disorders. Studies on schizophrenia and comorbid substance use are lacking. Future studies should focus on the effects of CBD on psychotic disorders in different stages of illness, together with the effects on comorbid substance use. These studies should use standardized measures to assess cannabis use. In addition, future efforts should be taken to study the relationship between the eCB system, GABA/glutamate, and the immune system to reveal the underlying neurobiology of the effects of CBD.


Author(s):  
Gordon MacNeil ◽  
B. Michelle Brazeal

This article presents information regarding the evolving understanding of the relationships between impulse-control disorders, compulsion-related disorders, and addictions (both substance-related and behavioral). The traditional model describing the relationship between impulse-control disorders and compulsion-related disorders is now considered overly simplistic. New research suggests that this relationship is complex, and distinctions between these disorders are not as solid as previously thought. Information about this dynamic relationship also has implications for substance use disorders and behavioral addictions.


Sign in / Sign up

Export Citation Format

Share Document